To keep drug prices high, pharma has been piling up the patents

Since 1990, the average number of patents per small-molecule drug approved in the U.S. has risen from 2.1 to 6.9, a growth driven mainly by nonprimary patents on excipients, usage methods, and delivery devices. These additional patents create patent thickets that postpone generic entry, keeping drug prices high without new clinical benefits.